Portfolio
Cutiss is a Swiss clinical-stage life-science company that provides patients who with acute scarring (especially due to burns, trauma and operations) with bio-engineered, customised human skin (their trademarked “denovoSkin”).
Visit WebsiteImmonuPhotonics is a biotechnology company that is developing a proprietary treatment for solid-tumour cancers. The company is headquartered in St Louis, Missouri, USA, with subsidiaries in Bern, Switzerland, and Tianjin, China.
Visit WebsiteScipio Bioscience is developing and industrialising a first sample preparation kit, designed to democratise single-cell sequencing experiments.
Visit WebsitePathoQuest enables screening for more than 1,200 pathogens with a single test instead of the multiple tests currently required, assisting with the rapid diagnosis of infectious diseases.
Visit WebsiteBiograil’s novel technology allows for the oral delivery of injectable pharmaceutical products.
Visit WebsiteLatest News Articles
CUTISS launches Series C financing round to advance the development of its personalized skin technology
CUTISS seeks to raise the Series C with the participation of existing and new investors to take its personalized skin therapy d
CUTISS announces positive Phase 2 clinical trial results for denovoSkin™
CUTISS AG has announced positive results from the Phase 2 clinical trial of its lead product denovoSkin™, in adult and adoles
Youngest patient ever treated with denovoSkin – a neonatal case
The paper published in Burns Open has presented the case of a four day-old neonate suffering from life threatening burns, invol